FOXO TECHNOLOGIES INC. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
FOXO TECHNOLOGIES INC. (FOXO) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $172.13 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-08-14
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2026-03-31 was $172.13K.
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-12-31 was $8.97M, a 44746.36% increase year-over-year.
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-09-30 was $12.27M, a 13856.85% increase year-over-year.
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2025-06-30 was $321.32K.
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2025 was $21.67M, a 1918.01% increase from fiscal 2024.
- FOXO TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2024 was $1.07M.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|
| 2026-03-31 | $172.13K 10-Q · filed 2026-05-15 | $9.14M derived: sum of 2 quarters · filed 2026-05-15 | $21.41M derived: sum of 3 quarters · filed 2026-05-15 | $21.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $21.24M derived: sum of 2 quarters · filed 2026-04-15 | $21.56M derived: sum of 3 quarters · filed 2026-08-14 | $21.67M 10-K · filed 2026-04-15 |
| 2025-09-30 | $12.27M 10-Q · filed 2025-11-10 | $12.59M derived: sum of 2 quarters · filed 2026-08-14 | $12.70M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $321.32K 10-Q · filed 2026-08-14 | $493.44K 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $107.89K derived: sum of 2 quarters · filed 2026-04-15 | $1.07M 10-K · filed 2026-04-15 | |
| 2024-09-30 | $87.89K 10-Q · filed 2025-11-10 | $1.05M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |